PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Clinical Studies Overview | Orbactiv® (oritavancin) for injection
Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial - Clinical Oncology News
The forefront of ovarian cancer therapy: update on PARP inhibitors - Annals of Oncology
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer | NEJM
Maintenance strategies in phase III clinical trials assessing poly... | Download Scientific Diagram
SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent's Label
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3
IJMS | Free Full-Text | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy | HTML
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) - Journal
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
sólo1 - Twitter Search / Twitter
